Page 8 - GB-RI-PierreFabre-Complet-INTERACTIF

06 INTEGRATED ANNUAL REPORT 2021 - PIERRE FABRE EDITORIAL FROM COMPANY LEADERS The company has proven its ability to adapt The first year of implementing the Transformation Plan unfolded against the backdrop of an unprecedented health and economic crisis. How would you sum up this extraordinary year? Roch Doliveux: This year was particularly impressive! Despite the scale of external challenges, I was struck, just like the whole Supervisory Board, by everyone’s ability to come together to respond to the pandemic and its economic impacts, while at the same time implementing the transformation. Pierre-Yves Revol: This period we are currently experiencing requires us to be highly responsive and agile. The company has demonstrated this, for example through implementing a cost-saving plan which has enabled the impact of the loss of business on the operating result to be offset. Equally, we should not overlook its role as a socially responsible company, helping a number of health establishments, either directly or through the Foundation, with donations of health care products and masks, for example. Eric Ducournau: First and foremost, we were pleased to have been able to ensure the health safety of employees within the company during this period. Secondly, we were pleased to have been able to ensure service continuity regarding patients and customers, especially in the field of pharmaceuticals, and I’m referring in particular to those who use our cancer treatments. Lastly, we stayed on course with our Transformation Plan, particularly in terms of deploying our new information systems and changes in the organization. The company’s employees have shown their commitment and ability to adapt during this highly complicated period. How did 2020 demonstrate the sincerity of Pierre Fabre’s Purpose? RD: Our Purpose keeps us going on a daily basis, and the way the company came together to respond to the pandemic demonstrated its strength. It is also what guides our strategy and our decisions, and the way in which we implement them, whether they be investments, product launches, R&D projects, etc. The transformation projects undertaken in 2020 also make this guiding principle a reality. ED: As an example, in December we entered into a partnership with the EspeRare Foundation to develop research on XLHED, a serious genetic disorder with a dermatological impact, which affects around 500 infants every year worldwide. Acting on this rare condition is a concrete representation of our Purpose: “Every time we care for a single person, we make the whole world better.” “We have set ambitious goals for ourselves to achieve by 2022: triple our operating profit, have 70 % of our business outside of France, and rebalance our portfolio between pharmaceuticals and dermo-cosmetics.” Eric Ducournau, CEO of the Pierre Fabre group